Use of heterocyclic carboxamides to treat anemia
CA 2468083 C · Owner: Fibrogen, Inc. · Inventors: Arend, Michael P.; Wang, Qingjian; Lin, Al Y.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods for treating erythropoietinassociated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning or preventing , erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 6, 2002 and granted February 23, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 6, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 6, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.